‘Zoom fatigue’ is taxing the brain. Here's why that happens. nationalgeographic.com/science/2020/0… via Nat Geo Science

this sport is more important to society than NFTs

MetaMask 🦊 is an amazing app for many reasons. One reason I like especially is that even though it works just fine, the window object of the app is (almost) unusable! If you're into Browser JavaScript security, come learn about what we call "scuttling" - by LavaMoat 🌋 Well..

A delivery driver who had almost finished crossing the road is shoved off his bike to make way for Joe Biden. This is what liberal democracy looks like. These people are better than you and don't you forget that.

The Clipper Airdrop has just went live! All rewards are based on your on-chain activity. Connect and check if you're eligible: 👉 clipperdex.net

Dasa e Amil se unem e criam a segunda maior rede de hospitais do país. A nova empresa já nasce com 25 hospitais, 30 centros oncológicos e 23 centros médicos. Combinada, a receita líquida estimada é da ordem de R$ 10,6 bilhões. medicinasa.com.br/rede-americas-…

A DASA Oncologia, agora, é Americas! Somos uma das maiores redes de hospitais e clínicas de oncologia do Brasil.

No Joke: Iran's regime was to host today a U.N. Human Rights Council event: “Situation of the women and girls in the Islamic Republic of Iran: latest breakthroughs.” Same regime that beats, blinds and rapes women who defend their rights. Event was just canceled, no reasons given.

#ASCO17 FASCO Penn Medicine - Abramson Cancer Center Lynn Schuchter discusses importance of communicating prognosis in pts with advanced #melanoma

Nivolumab seem to be safe in #kidneycancer mRCC with brain mets, but caution w/ rapid progression. #ASCO2017 #MOCnaASCO BP MOC Brasil

2 estudos com IPI/NIVO em metástases cerebrais de Melanoma: 45-55% de resposta no SNC!! Provável mudança da pratica. #ASCO17 #MOCnaASCO

2 trials of Melanoma Brain Mets treated with IPI/NIVO. Itracranial response rate of 45-55%. Probable practice change #ASCO17 #MOCnaASCO

28% de paciente com melanoma vivos após 5 anos de dabrafenibe/trametinibe. Terapia alvo com plateau. #ASCO17 #MOCnaASCO MOC Brasil

28% of patients with metastatic melanoma alive after 5y using dabrafenib/trametinib. #ASCO17 #MOCnaASCO MOC Brasil

KEYNOTE-045 updated results. Even higher ORR due to more CR/PR over time. #ASCO17 #MOCnaASCO BP MOC Brasil joaquim bellmunt Toni Choueiri, MD

#Pembrolizumab + #Pazopanib: High incidence of LFTs increase (too toxic). Toni Choueiri, MD BP MOC Brasil #MOCnaASCO #ASCO17

Pembro should be the new SOC for bladder cancer. #ASCO17 #MOCnaASCO BP MOC Brasil x.com/drchoueiri/sta…

Unbelievable. He actually did bring the Middle East together.